Latest Hematopoietic stem cell transplantation Stories
Phase 1 Trial of BL-8040 expected to begin in Q2 2014; top-line results expected in H2 2014 JERUSALEM, Jan.
An exciting breakthrough is offering hope for the treatment of blood diseases such as leukemia using artificial bone marrow.
NEW YORK, Jan. 8, 2014 /PRNewswire/ -- Bone marrow transplants are a $1.3 billion market and the fastest-growing hospital procedure in the U.S.
Researchers have been able to reprogram the body’s immune system to fight leukemia, with 89 percent of children and adults in a series of clinical trials showing no evidence of cancer after receiving a personalized cell therapy.
Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors.
Some babies diagnosed with and treated for a bone marrow failure disorder, called Diamond Blackfan Anemia, may actually be affected by a very rare anemia syndrome that has a different disease course and treatment.
Bone Marrow Transplantation is a peer-reviewed medical journal published monthly by Nature Publishing Group. As of May 2012, the editor-in-chief is J.M. Goldman (UK). The journal publishes high quality, original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation in humans. The broad scope of the journal thus encompasses topics such as stem cell biology, kinetics and cytokine control, transplantation immunology, HLA and matching...
- totally perplexed and mixed up.